Literature DB >> 19015958

Antisense makes sense in engineered regenerative medicine.

Yongchang Yao1, Chunming Wang, Rohan R Varshney, Dong-An Wang.   

Abstract

The use of antisense strategies such as ribozymes, oligodeoxynucleotides (ODNs) and small interfering RNA (siRNA) in gene therapy, in conjunction with the use of stem cells and tissue engineering, has opened up possibilities in curing degenerative diseases and injuries to non-regenerating organs and tissues. With their unique ability to down-regulate or silence gene expression, antisense oligonucleotides are uniquely suited in turning down the production of pathogenic or undesirable proteins and cytokines. Here, we review the antisense strategies and their applications in regenerative medicine with a focus on their efficacies in promoting cell viability, regulating cell functionalities as well as shaping an optimal microenvironment for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015958     DOI: 10.1007/s11095-008-9772-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  115 in total

1.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

Review 2.  Life-or-death decisions by the Bcl-2 protein family.

Authors:  J M Adams; S Cory
Journal:  Trends Biochem Sci       Date:  2001-01       Impact factor: 13.807

3.  Inhibition of GSK3 promotes replication and survival of pancreatic beta cells.

Authors:  Rainer Mussmann; Marcus Geese; Friedrich Harder; Simone Kegel; Uwe Andag; Alexander Lomow; Ulrike Burk; Daria Onichtchouk; Cord Dohrmann; Matthias Austen
Journal:  J Biol Chem       Date:  2007-01-22       Impact factor: 5.157

4.  Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury.

Authors:  Ramesh Natarajan; Fadi N Salloum; Bernard J Fisher; Rakesh C Kukreja; Alpha A Fowler
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

5.  Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy.

Authors:  T Tomita; E Takeuchi; N Tomita; R Morishita; M Kaneko; K Yamamoto; T Nakase; H Seki; K Kato; Y Kaneda; T Ochi
Journal:  Arthritis Rheum       Date:  1999-12

6.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

7.  Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors:  F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

8.  Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method.

Authors:  R S Poston; M J Mann; E G Hoyt; M Ennen; V J Dzau; R C Robbins
Journal:  Transplantation       Date:  1999-09-27       Impact factor: 4.939

9.  Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes.

Authors:  S T Crooke; K M Lemonidis; L Neilson; R Griffey; E A Lesnik; B P Monia
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  9 in total

1.  siRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells.

Authors:  Morten Ø Andersen; Jens V Nygaard; Jorge S Burns; Merete K Raarup; Jens R Nyengaard; Cody Bünger; Flemming Besenbacher; Kenneth A Howard; Moustapha Kassem; Jørgen Kjems
Journal:  Mol Ther       Date:  2010-08-31       Impact factor: 11.454

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

3.  Sustained local delivery of siRNA from an injectable scaffold.

Authors:  Christopher E Nelson; Mukesh K Gupta; Elizabeth J Adolph; Joshua M Shannon; Scott A Guelcher; Craig L Duvall
Journal:  Biomaterials       Date:  2011-11-05       Impact factor: 12.479

4.  Characterization and evaluation of a peptide-based siRNA delivery system in vitro.

Authors:  Baoling Chen; Kimoon Yoo; Wen Xu; Ran Pan; Xiao Xia Han; P Chen
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

5.  Optimal construction and delivery of dual-functioning lentiviral vectors for type I collagen-suppressed chondrogenesis in synovium-derived mesenchymal stem cells.

Authors:  Feng Zhang; Yongchang Yao; Ruijie Zhou; Kai Su; Fudiman Citra; Dong-An Wang
Journal:  Pharm Res       Date:  2010-11-06       Impact factor: 4.200

6.  Controlling mesenchymal stem cell gene expression using polymer-mediated delivery of siRNA.

Authors:  Danielle S W Benoit; Molly E Boutin
Journal:  Biomacromolecules       Date:  2012-10-11       Impact factor: 6.988

Review 7.  siRNA applications in nanomedicine.

Authors:  Talar Tokatlian; Tatiana Segura
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 May-Jun

8.  Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells.

Authors:  Khanh Nguyen; Phuong Ngoc Dang; Eben Alsberg
Journal:  Acta Biomater       Date:  2012-08-16       Impact factor: 8.947

9.  Localized, targeted, and sustained siRNA delivery.

Authors:  Melissa D Krebs; Eben Alsberg
Journal:  Chemistry       Date:  2011-02-21       Impact factor: 5.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.